IP Library › Granted Patent US 12,397,030
Granted Patent B2
US 12,397,030 · App. 17/784,168 · Granted Aug 26, 2025

Polyphenol compositions and uses thereof

Inventors: Annalouise O'Connor (Gig Harbor, WA); Mark Houston (Nashville, TN)
Assignee: METAGENICS LLC
A61K36/185A61K31/01A61K31/05A61K31/352A61P3/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,397,030
App. No.
17/784,168
Granted
Aug 26, 2025
Kind
B2
Abstract

This disclosure provides a composition and a method for enhancing urolithin B production. As a result of this, due to known impact of urolithin B, this can enhance reverse cholesterol transport and HDL function and management of plasma lipid profile through enhanced production of urolithin B from pomegranate polyphenols by administering a composition comprising a synergistic mixture of pomegranate polyphenols, lycopene and quercetin. The improved HDL function and lipid profile of such composition may be attributed to the enhanced urolithin B production made possible by the combination. Increasing the levels of urolithin B through modulation of the intestinal microbiome metabolism of pomegranate polyphenols is a potential therapeutic target for managing these diseases.

Claims (13)

1. A composition comprising:

I) a synergistic combination consisting essentially of:

i) pomegranate extract with a total polyphenol content of 50% by weight or greater, and a punicalagin content of 30% by weight or greater;

ii) quercetin; and

iii) lycopene;

II) Vitamin E; and

III) at least one inactive ingredient selected from the group consisting of microcrystalline cellulose, silicon dioxide, magnesium stearate, and combinations thereof;

wherein the ratio of the total weight of the pomegranate polyphenols to total weight quercetin and lycopene in the composition is from about 1:0.1 to about 1:10;

wherein the composition is in the form of a serving, and wherein the pomegranate extract is present in the serving in an amount of from about 200 to about 600 mg, the quercetin is present in the serving in an amount of from about 500 to about 1500 mg, and the lycopene is present in the serving in an amount of from about 1 to about 50 mg; and

wherein the composition is encapsulated in hydroxypropyl methylcellulose or hypromellose and is in the form of at least one tablet, capsule, or caplet.

2. The composition of claim 1 , wherein the pomegranate extract is pomegranate polyphenols.

3. The composition of claim 1 , wherein the pomegranate extract is present in an amount of from about 15 wt. % to about 40 wt. %, the quercetin is present in an amount of from about 35 wt. % to about 85 wt. %, and the lycopene is present in an amount of from about 0.1 wt. % to about 5 wt. %, each based on 100 parts by weight of the pomegranate extract, quercetin, and lycopene.

4. The composition of claim 1 , comprising 28.2% by weight pomegranate polyphenols and 71.8% by weight of the combination of quercetin and lycopene.

Assignments (3)
SECURITY INTEREST Recorded Dec 22, 2025
From: METAGENICS LLC
To: WHITEHORSE CAPITAL ORIGINATION, LLC, AS AGENT
Reel/Frame 073293/0381 →
CHANGE OF NAME Recorded Feb 16, 2024
From: METAGENICS, INC.
To: METAGENICS LLC
Reel/Frame 066624/0241 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2022
From: O'CONNOR, ANNALOUISE; HOUSTON, MARK
To: METAGENICS, INC.
Reel/Frame 060961/0908 →
Continuity (2)
Provisional Application 62952745 · Dec 23, 2019
Related Publication 20230030835A1 · Feb 2, 2023
References Cited (64)
US 7638640B2 · Seeram et al. · 2009 [cited by applicant]
US 7897791B2 · Seeram et al. · 2011 [cited by applicant]
US 7919636B2 · Seeram et al. · 2011 [cited by applicant]
US 8648112B2 · Seeram et al. · 2014 [cited by applicant]
US 10537516B2 · Zhang et al. · 2020 [cited by applicant]
US 20040131656A1 · Roufs · 2004 [cited by examiner]
US 20080248129A1 · Bartunek et al. · 2008 [cited by applicant]
US 20190224193A1 · Reid et al. · 2019 [cited by applicant]
US 20200085895A1 · Patel et al. · 2020 [cited by applicant]
US 20210369674A1 · Wan · 2021 [cited by applicant]
WO 2005107729A1 · 2005 [cited by applicant]
WO 2012088519A2 · 2012 [cited by applicant]
Zhang et al., Aquaculture, 578, 2024, pp. 1-7. [cited by examiner]
Pisipati et al., Journal of basic clinical pharmacy, May 2012, pp. 261-264. [cited by examiner]
UCLA health, 2022, pp. 1-6. [cited by examiner]
Adams LS, et al. Adams, Lynn S., et al. “Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro.” Cancer Prevention Research 3.1, 108-113 (2010). [cited by applicant]
Cahill LE, et al. Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men. J Lipid Res., 60(8) 1457-1464 (2019). [cited by applicant]
Cho, et al. “Chemopreventive activity of ellagitannins and their derivatives from black raspberry seeds on HT-29 colon cancer cells.” Food & function 6.5, 1675-1683 (2015). [cited by applicant]
Cortes-Martin A, et al., “The gut microbiota urolithin metabotypes revisited: the human metabolism of ellagic acid is mainly determined by aging.” Food & function 9.8, 4100-4106 (2018). [cited by applicant]
Cortes-Martin A, et al., “Urolithin metabotypes can anticipate the different restoration of the gut microbiota and anthropometric profiles during the first year postpartum.” Nutrients 11.9: 2079 (2019). [cited by applicant]
Daniel EM, et al., “The effects of pH and rat intestinal contents on the liberation of ellagic acid from purified and crude ellagitannins.” Journal of Natural Products 54.4, 946-952 (1991). [cited by applicant]
Zhao W, et al. “Preparative isolation and purification of urolithins from the intestinal metabolites of pomegranate ellagitannins by high-speed counter-current chromatography.” J Chromatogr B Analyt Technol Biomed Life … [cited by applicant]
Derosa G, et al. “Ellagic Acid and Its Role in Chronic Diseases”, Advances in Experimental Medicine and Biology, Anti-inflammatory Nutraceuticals and Chronic Diseases vol. 928, 473-479 (2016). [cited by applicant]
Ebtehaj S, et al. “HDL (high-density lipoprotein) cholesterol efflux capacity is associated with incident cardiovascular disease in the general population: a case-control study from the PREVEND cohort.” Arterioscler Thr… [cited by applicant]
Etxeberria U, et al. “Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats.” The Journal of nutritional biochemistry 26.6, 651-660 (2015). [cited by applicant]
Fadaei R, et al. “Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis”. Scientific Reports, 8(1), 11691—(2018). [cited by applicant]
Garcia-Villalba R, et al. “Gastrointestinal simulation model TWIN-SHIME shows differences between human urolithin-metabotypes in gut microbiota composition, pomegranate polyphenol metabolism, and transport along the int… [cited by applicant]
Gibson GR, et al. “Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics.” Nat Rev Gastroenterol Hepatol.… [cited by applicant]
Gimenez-Bastida JA, et al. “Urolithins, ellagitannin metabolites produced by colon microbiota, inhibit quorum sensing in Yersinia enterocolitica: phenotypic response and associated molecular changes.”.Food Chem.132(3):1… [cited by applicant]
Gonzalez-Sarrias A, et al. “Clustering according to urolithin metabotype explains the interindividual variability in the Improvement of cardiovascular risk biomarkers in overweight?obese individuals consuming pomegranat… [cited by applicant]
Guerin M, et al. Association of Serum Cholesterol Efflux Capacity With Mortality in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, J Am Coll Cardiol. 72(25):3259… [cited by applicant]
Kajani S, et al. “Unravelling HDL—Looking beyond the Cholesterol Surface to the Quality Within.” Int J Mol Sci, 19(7) (2018). [cited by applicant]
Kawabata K, et al. “Role of Intestinal Microbiota in the Bioavailability and Physiological Functions of Dietary Polyphenols”. Molecules, 24(2) (2019). [cited by applicant]
Khera AV, et al. “Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis.” N Engl J Med. 364(2):127-135 (2011). [cited by applicant]
Lee G, et al. “Anti-inflammatory and antioxidant mechanisms of urolithin B in activated microglia.” Phytomedicine, 55:50-57 (2019). [cited by applicant]
Lei F, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;796(1):189-194. “Pharmacokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract.” J Chromatogr B Analyt Technol Biome… [cited by applicant]
Li CC, et al. “Tomato Powder Inhibits Hepatic Steatosis and Inflammation Potentially Through Restoring SIRT1 Activity and Adiponectin Function Independent of Carotenoid Cleavage Enzymes in Mice.” Mol Nutr Food Res., 62(… [cited by applicant]
Nie J, et al. “Quercetin reduces atherosclerotic lesions by altering the gut microbiota and reducing atherogenic lipid metabolites.” J Appl Microbiol. 127(6):1824-1834 (2019). [cited by applicant]
Piwowarski JP, et al. “Urolithins, gut microbiota-derived metabolites of ellagitannins, inhibit LPS-induced inflammation in RAW 264.7 murine macrophages.” Mol Nutr Food Res.59(11):2168-2177 (2015). [cited by applicant]
Porras D, et al. “Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.” Free … [cited by applicant]
Pereira-Caro G, et al. “In vitro colonic catabolismof orange juice (poly) phenols.” Mol Nutr Food Res. 59(3):465-475 (2015). [cited by applicant]
Qiu Z, et al. “In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells.” Food Chem Toxicol. 59:428-437 (2013). [cited by applicant]
Rodriguez J, et al. “Urolithin B, a newly identified regulator of skeletal muscle mass.” J Cachexia Sarcopenia Muscle. 8(4):583-597 (2017). [cited by applicant]
Romo-Vaquero M, et al. “Deciphering the Human Gut Microbiome of Urolithin Metabotypes: Association with Enterotypes and Potential Cardiometabolic Health Implications.” Mol Nutr Food Res. 63(4):e1800958 (2019). [cited by applicant]
Savi M, et al. “In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats.” Cardiovasc Diabetol. 16(1):80 (2017). [cited by applicant]
Seeram NP, et al. “Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate ( [cited by applicant]
Seeram NP, et al. “Pomegranate Juice Ellagitannin Metabolites Are Present in Human Plasma and Some Persist in Urine for Up to 48 Hours.” J Nutr. 136(10):2481-2485 (2006). [cited by applicant]
Speer T, et al. “Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-like Receptor-2.” Immunity. 38(4):754-768 (2013). [cited by applicant]
Tamura M, et al. “Quercetin metabolism by fecal microbiota from healthy elderly human subjects.” PLoS One. 12(11):e0188271 (2017). [cited by applicant]
Tomas-Barberan FA, et al. “Ellagic Acid Metabolism by Human Gut Microbiota: Consistent Observation of Three Urolithin Phenotypes in Intervention Trials, Independent of Food Source, Age, and Health Status.” J Agric Food … [cited by applicant]
Manach C, et al. “Addressing the inter-individual variation in response to consumption of plant food bioactives: Towards a better understanding of their role in healthy aging and cardiometabolic risk reduction.” Mol Nut… [cited by applicant]
Wang S, et al. “Bacteriostatic Effect of Quercetin as an Antibiotic Alternative In Vivo and Its Antibacterial Mechanism In Vitro.” Journal of Food Prot. 81(1):68-78 (2018). [cited by applicant]
Watanabe J, et al. “Proteomic profiling following immunoaffinity capture of high-density lipoprotein: Association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoi… [cited by applicant]
Wiese M, et al. “Prebiotic Effect of Lycopene and Dark Chocolate on Gut Microbiome with Systemic Changes in Liver Metabolism, Skeletal Muscles and Skin in Moderately Obese Persons.” Biomed Res Int. 2019:4625279 (2019). [cited by applicant]
Wu S, et al., “Diverse Phytochemicals and Bioactivities in the Ancient Fruit and Modern Functional Food Pomegranate ( [cited by applicant]
Xia H, et al. “Dietary Tomato Powder Inhibits High-Fat Diet-Promoted Hepatocellular Carcinoma with Alteration of Gut Microbiota in Mice Lacking Carotenoid Cleavage Enzymes.” Cancer Prev Res (Phila). 11(12):797-810 (2018… [cited by applicant]
Yuan T, et al. “Pomegranate's Neuroprotective Effects against Alzheimer's Disease Are Mediated by Urolithins, Its Ellagitannin-Gut Microbial Derived Metabolites.” ACS Chem Neurosci. 7(1):26-33 (2016). [cited by applicant]
Zhao L, et al. “A combination of quercetin and resveratrol reduces obesity in high-fat diet-fed rats by modulation of gut microbiota.” Food Funct. 8(12):4644-4656 (2017). [cited by applicant]
Zhao W, et al. “A Novel Candidate for Prevention and Treatment of Atherosclerosis: Urolithin B Decreases Lipid Plaque Deposition in apoE?/? Mice and Increases Early Stages of Reverse Cholesterol Transport in ox-LDL Trea… [cited by applicant]
DaSilva NA, Nahar PP, Ma H, Eid A, Wei Z, Meschwitz S, Zawia NH, Slitt AL, Seeram NP. Pomegranate ellagitannin-gut microbial-derived metabolites, urolithins, inhibit neuroinflammation in vitro. Nutr Neurosci. Mar. 2019,… [cited by applicant]
International Search Report for PCT/US2020/066905 dated Apr. 26, 2021, 5 pages. [cited by applicant]
Eleonora Turrini, Lorenzo Ferruzzi, Carmela Fimognari, “Potential Effects of Pomegranate Polyphenols in Cancer Prevention and Therapy”, Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 938475, 19 pages, … [cited by applicant]
Shahkoomahally et al., “Profiling phenolic compounds in juice and peel of fourteen pomegranate ( [cited by applicant]
University Hospitals, Health & Wellness Library Nutrition Facts: Pomegranates, found at: https://www.uhhospitals.org/health-information/health-and-wellness-library/article/nutritionfacts-v1/pomegranates-raw-1-pomegranat… [cited by applicant]